生化复发前列腺癌的影像学检查策略优化
MRI骨盆发现远处转移(骨盆骨转移或髂总动脉分叉以上淋巴结)的患者,CT和骨扫描阳性率更高,相关系数分别为0.81和0.91(p<0.01)。基于风险分层和检查选择标准的影像策略可提高传统影像的收益。
要点
- MRI骨盆显示远处转移时,CT和骨扫描阳性可能性更高。
- MRI表现可用于预测CT/骨扫描的附加价值。
- PSMA PET-CT可及性有限时,风险分层策略可优化资源。
核心结论
- 基于风险分层和检查选择标准的影像策略可更合理利用资源并提高传统影像方法收益。
- MRI前列腺表现可预测CT/核医学骨扫描的附加价值,从而简化其使用。
研究设计与样本
- 单中心回顾性影像审查,经内部审查委员会伦理批准。
- 通过PACS档案搜索数据库,以「PSA」和「prostatectomy」为检索词,检索MRI、CT和核医学骨扫描三种检查。
- 记录所有进行的PSMA PET-CT检查。
关键影像表现/征象
- MRI骨盆显示远处转移,即骨盆骨转移或髂总动脉分叉以上淋巴结受累。
- MRI骨盆M1病变与CT胸部/腹部/骨盆远处转移的Pearson相关系数为0.81(p<0.01)。
- MRI骨盆M1病变与核医学骨扫描远处转移的Pearson相关系数为0.91(p<0.01)。
诊断标准与关键数值
- 生化复发定义为两次独立检测PSA≥0.2 ng/ml。
- MRI骨盆M1病变定义为骨盆骨转移或髂总动脉分叉以上淋巴结受累。
临床应用与阅片要点
- 可利用MRI骨盆是否显示远处转移来预判CT和骨扫描的阳性概率,辅助决定是否加做。
- 在PSMA PET-CT可及性有限时,按风险分层选择传统影像可提高收益。
局限性
- 单中心回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To assess the utility of magnetic resonance imaging (MRI) in addition to the additive benefit of the conventional imaging techniques, computed tomography (CT) and nuclear medicine (NM) bone scintigraphy, for investigation of biochemical recurrence (BCR) post-prostatectomy where access to prostate specific membrane antigen (PSMA) positron-emission tomography (PET)-CT is challenging.
MATERIALS AND METHODS: Relevant imaging over a 5-year period was reviewed. Ethical approval was granted by the internal review board. All patients with suspected BCR, defined as a PSA ≥0.2 ng/ml on two separate occasions, underwent a retrospective imaging review. This was performed on PACS archive search database in a single centre using search terms "PSA" and "prostatectomy" in the three imaging methods; MRI, CT, and NM bone scintigraphy. All PSMA PET CT performed were recorded.
RESULTS: One hundred and eighty-five patients were identified. Patients with an MRI pelvis that demonstrated distant metastases (i.e., pelvic bone metastases or lymph node involvement more cranial to the bifurcation of the common iliac arteries) were more likely to have a positive CT and/or NM bone scintigraphy. The Pearson correlation coefficient between the findings of M1 disease at MRI pelvis and the presence of distant metastases at CT thorax, abdomen, pelvis and NM bone scintigraphy was calculated at 0.81 (p<0.01) and 0.91 (p<0.01) respectively.
CONCLUSION: An imaging strategy based on risk stratification and technique-specific selection criteria leads to more appropriate use of resources, and in turn, increases the yield of conventional imaging methods. MRI prostate findings can be used to predict the additive value of CT/NM bone scintigraphy allowing a more streamlined approach to their use.
引用
- Briody, Sheehan, Hanley, et al. Biochemically recurrent prostate cancer: rationalisation of the approach to imaging. Clin Radiol. 2023. PMID: 37085338. doi:10.1016/j.crad.2023.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。